Green Alpha Advisors LLC Raises Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Green Alpha Advisors LLC raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 132.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,361 shares of the company's stock after purchasing an additional 32,732 shares during the quarter. CRISPR Therapeutics accounts for 2.1% of Green Alpha Advisors LLC's portfolio, making the stock its 10th largest holding. Green Alpha Advisors LLC owned approximately 0.07% of CRISPR Therapeutics worth $1,952,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Wood Tarver Financial Group LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at $30,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $36,000. Western Pacific Wealth Management LP boosted its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at $71,000. Finally, Spire Wealth Management grew its holdings in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock worth $78,000 after purchasing an additional 1,482 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at approximately $3,288,822.60. The trade was a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now directly owns 180,890 shares of the company's stock, valued at $7,673,353.80. This trade represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,953 shares of company stock valued at $736,087 in the last 90 days. 4.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a report on Friday, May 16th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a report on Wednesday, February 12th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Citigroup decreased their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating on the stock in a research report on Tuesday, February 18th. Finally, Chardan Capital cut their price objective on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Trading Up 3.4%

Shares of NASDAQ:CRSP traded up $1.29 during trading on Thursday, hitting $39.34. 1,352,901 shares of the company's stock traded hands, compared to its average volume of 1,713,148. The company has a 50-day moving average price of $36.56 and a 200-day moving average price of $41.27. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The company has a market cap of $3.40 billion, a price-to-earnings ratio of -9.00 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter in the prior year, the company posted ($1.43) EPS. CRISPR Therapeutics's quarterly revenue was up 71.6% compared to the same quarter last year. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.